![](https://qtxasset.com/styles/breakpoint_sm_default_480px_w/s3/fiercebiotech/1586349438/Arrakis%20management%20April%202020.jpg?uZNTLVMDrKjiozmlo1QMQEM8isYqufDO&itok=lw6lrLrr)
Arrakis Therapeutics has been dodging pharma suitors since its early days, keeping its head down, building its RNA-targeting technology and “politely declining” advances “because we weren’t ready.”
Arrakis Therapeutics has been dodging pharma suitors since its early days, keeping its head down, building its RNA-targeting technology and “politely declining” advances “because we weren’t ready.”